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Patients with myeloproliferative neoplasms (MPNs), polycythemia vera, essential
thrombocythemia, and primary myelofibrosis, have an increased risk of thrombosis. Risk of
recurrent thrombosis can be reducedwith antithrombotic therapy and/or cytoreduction, but
the optimal long-term management in patients with MPN with a history of venous
thromboembolism (VTE) is unknown, and clinical practice is heterogeneous. We performed
a systematic review and meta-analysis of randomized trials and observational studies
evaluating anticoagulant and/or antiplatelet therapy, with or without cytoreduction, in MPN
patients with a history of VTE. A total of 5675 unique citations were screened for eligibility.
No randomized trials were identified. Ten observational studies involving 1295 patients
with MPN were included in the analysis. Overall, 23% had an arterial or recurrent venous
thrombotic event on follow-up. The recurrence risk was lowest for patients on oral
anticoagulation plus cytoreduction (16%); 55 of 313 (18%) with vitamin K antagonists (VKA)
and 5 of 63 (8%) with direct oral anticoagulants (DOACs). In 746 analyzed patients, the risk of
recurrent VTE ranged up to 33% (median 13%) and was low in 63 DOAC plus cytoreduction-
treated patients (3.2%). All types of antithrombotic treatments were associated with a lower
risk of recurrent VTE when combined with cytoreduction. Most studies had a high risk of
bias, whereas clinical and statistical heterogeneity led to inconsistent and imprecise
findings. In summary, evidence on the optimal antithrombotic treatment of VTE in patients
with MPN is based on observational studies only with low certainty for all strategies. Our
data suggest that a combination of anticoagulation and cytoreduction may provide the
lowest recurrence risk.
Introduction
Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) belong to the
BCR-ABL1–negative myeloproliferative neoplasms (MPNs).1 MPNs are characterized by clonal
proliferation of terminal myeloid cells with variable predominance of cell lines in the peripheral blood.
PV or ET can also transform to myelofibrosis. All MPNs can progress into acute myeloid leukemia.
Arterial and venous thrombosis are common events in patients with MPN and have a high incidence
across all MPN subtypes.2 The incidence of thrombotic events is highest in patients with PV (5.5 per 100
patient-years) and similar in patients with ET (1-3 per 100 patient-years) and PMF (2 per 100 patient-
years).3-5 Thrombosis can occur in patients with clinically overt MPN but can also be the first presenting
symptom preceding diagnosis of MPN in up to 40% of patients with splanchnic vein thrombosis.6
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Its pathophysiology is generally multifactorial. Traditional risk factors
of MPN-associated thrombosis include advanced age (.60 years),
sex, and a history of thrombosis. Leukocytosis and the presence of
the JAK2V617F mutation have been identified as specific risk
factors for thrombosis in patients with MPN, whereas the risk of
thrombosis appears to be lower in those with CALR mutation or
triple-negative MPN.7-9 Although arterial thrombosis is more
prevalent, a recent population-based study of 9429 patients with
MPN and 35820 matched controls found the risk of venous
thromboembolism (VTE) up to 3 times higher in patients with MPN
than in controls at all time points during 5-year follow-up.2 Although
VTE manifests most often as deep vein thrombosis of the leg or
pulmonary embolism, VTE also occurs relatively frequently at
uncommon sites such as splanchnic or cerebral veins in patients
with MPN.6,10,11 Patients with MPN have a higher risk of recurrence
compared with individuals without MPN but the risk of recurrence
may differ per site of VTE.12
One of the main therapeutic goals in MPN treatment is to prevent
thrombosis and recurrence of thrombosis, but the optimal
antithrombotic strategy and treatment duration are uncertain.12-14
Antiplatelet therapy has proven to be effective for primary
prevention of thrombotic complications in PV, but evidence for
long-term prevention of recurrent thrombosis in patients with MPN
is limited.15-17 A recent systematic review on antithrombotic therapy
in essential thrombocythemia showed that evidence on the risk-
benefit ratio of antiplatelet therapy was highly uncertain but did not
report on the use of oral anticoagulants.17 In the general population,
direct oral anticoagulants (DOACs) have been shown to be at least
as effective as vitamin K antagonists (VKA) for prevention of
recurrent VTE, but with a lower rate of major bleeding complica-
tions. DOACs are currently the first-choice treatment of acute VTE
in the general population. Based on recent studies, DOACs can
also be given for treatment of cancer-associated acute VTE, but
data on DOACs in patients with MPN are scarce.18-20 Cytoreduc-
tive treatment has demonstrated to play an important role in the
prevention of thrombosis in patients with MPN and risk reduction of
recurrent arterial thrombosis, but its efficacy in patients with
a history of VTE is uncertain.12,13
BecauseMPNs are chronic diseases, the risk of recurrent thrombosis
remains increased, and therefore, an argument can be made for
indefinite treatment. We performed a systematic review with the aim
to assess the efficacy (ie, recurrent thrombosis) and safety (ie,
bleeding) of antithrombotic treatments with or without cytoreductive
therapy in patients with MPN with a history of VTE.
Materials and methods
Search strategy
We systematically searched Medline, Embase, The Cochrane
Central Register of Controlled Trials, Web of Science conference
proceedings, clinicaltrials.gov, and the World Health Organization
International Clinical Trials Registry Platform, with the last paper
identified on February 5, 2020. Studies identified by the electronic
search as eligible for inclusion in the review were used as “seeds”
for the “related article” feature in PubMed and “find similar” feature
in Embase to identify more potentially relevant articles. A citation
search was performed for these studies in Web of Science to
identify articles that have cited these. Additionally, reference lists of
the included studies and of previous reviews on the subject were
hand searched for potentially relevant studies. We did not apply any
language or date restrictions. Relevant terms in the search strategy
are specified in the supplemental Data; the full search strategy is
available upon request. This systematic review was registered at the
Prospective Register of Systematic Reviews (PROSPERO) In-
ternational Prospective Register of Systematic Reviews as
#CRD42019112344.
Selection of studies
Two authors (E.N.H. and M.N.L.) screened all titles and abstracts
identified by the search strategy independently for potentially
eligible studies, using Rayyan.21 Studies were eligible if they met all
of the following criteria: (1) were a randomized controlled trial or
observational study with at least 10 patients; (2) included adults
(age$18 years) with an MPN (PV, ET, PMF, or pre-PMF) diagnosed
according to the contemporary diagnostic World Health Organiza-
tion criteria at the time of study conduct; (3) included patients with
a history of VTE; (4) evaluated anticoagulant therapy and/or
antiplatelet therapy with or without cytoreductive treatment,
compared with another, no treatment, or placebo; and (5) reported
data on recurrent thrombotic or bleeding events. Conference
abstracts were only considered if sufficient data were available for
data extraction. Eligible publications were reviewed in full text to
determine whether they met the inclusion criteria by 2 authors
independently (E.N.H. and M.N.L.). Any disagreements were
resolved through discussion between authors, and if necessary,
a third author (S.M.) was involved for the final vote. Agreement
between reviewers was measured with the Cohen k coefficient at
screening and full-text review.
Data extraction and synthesis
For every eligible study, data were extracted by 2 authors (E.N.H.
and M.N.L.) independently using a standardized data extraction
form. In case of uncertainties, we contacted the authors of the study
and requested additional information. Disagreements were resolved
as previously described. Outcomes of interest includes recurrent
thrombotic events, bleeding, all-cause mortality, fatal thrombosis,
and leukemic transformation. If eligible studies included a mixed
population with regard to history of thrombosis, we only extracted
data of the patients with a history of VTE for our primary outcome
analysis. Recurrent symptomatic VTE was defined as recurrent
deep vein thrombosis (of the leg or arm), pulmonary embolism,
cerebral (sino)venous thrombosis, and splanchnic vein thrombosis
(including portal vein thrombosis, hepatic vein thrombosis [Budd-
Chiari syndrome], or mesenteric vein thrombosis). Bleeding events,
including major, clinically relevant nonmajor, or minor bleeding
episodes, were defined by the International Society on Thrombosis
and Haemostasis (ISTH) criteria, the study’s local protocol, or
according to the treating physician. Other extracted data
included year of publication, number of participants, type and dose
of antithrombotic treatment, risk factors, and sites of thrombosis.
Treatment strategies
We aimed to evaluate the efficacy, by means of the recurrent
thrombosis rate, and safety, expressed as occurrence of bleeding
events for the following treatment strategies: (1) antiplatelet therapy
with or without cytoreduction; (2) oral anticoagulation with or
without cytoreduction; (3) oral anticoagulation plus antiplatelet
therapy with or with cytoreduction; and (4) cytoreduction only or no
antithrombotic or cytoreductive treatment. Long-term nonoral
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anticoagulant treatment (eg, low-molecular-weight heparin or synthetic
pentasaccharide) was not assessed separately.
Study quality assessment
Two authors (E.N.H. and M.N.L.) independently assessed risk of
bias for each study using the Cochrane ROBINS-I tool for
nonrandomized observational studies of interventions.22 Any
discrepancies were resolved by discussion or by involving a third
assessor (S.M.). Our treatment recommendations are based on
the quality of available evidence as outlined in the Grading of
Recommendations Assessment Development and Evaluation
tool.23
Statistical analysis
Primary and secondary outcomes were reported per antithrombotic
treatment strategy with and without concomitant cytoreductive
therapy. Using a random effects model, 95% confidence intervals
(CIs) were calculated for proportions and relative risks (RRs).
Heterogeneity of the pooled estimates was assessed using I2
statistics. Significant heterogeneity was defined as I2 .50%, and
considerable heterogeneity was defined as I2 .30%. All statistical
analyses were carried out using StatsDirect version 3.3.3
(StatsDirect Ltd, Chesire, United Kingdom).
Results
Study identification and selection
We identified 5787 studies using our search strategy. After removal
of 112 duplicates, we excluded 5430 papers based on title and
abstract screening. Screening agreement was excellent (k5 0.89).
We obtained 245 full-text papers for further evaluation and to
identify possibly overlapping study populations. By handsearching
and cross-referencing retrieved papers, we identified an additional
47 papers. A total number of 282 papers was subsequently
excluded after full-text evaluation: 77 did not meet the inclusion
criteria; 30 had overlapping study populations or data; 108
evaluated a different outcome or did not report on patients with
prior thrombotic events; 7 were reviews, surveys, or meta-analyses;
40 were abstract only with insufficient data for proper assessment;
and 20 papers had missing or unclear data. Agreement at full-text
stage was also excellent (k 5 0.91).
Twenty studies with unclear data (ie, no clear specification of
thrombotic events during follow-up or per treatment strategy) were
contacted for additional data; 12 responded, but only 2 provided
the requested data. Hence, the other 10 studies were excluded
because of missing data. Finally, we included 10 nonrandomized
observational studies in this systematic review with a total number
of 1295 participants (Figure 1).24-33
Study characteristics
Characteristics of the included studies are presented in Table 1. No
randomized controlled trials were identified. The included studies
were predominantly retrospective, single center cohort studies,
conducted in European centers. Study populations size ranged
from 14 to 494 patients, and the median duration of follow-up was
between 2.1 and 10 years. The median age of study participants
ranged from 47 to 75 years and 57% of the overall study population
was female. ET was the most prevalent MPN (54%), followed by PV
(37%). Of 1295 patients in the included studies, 87% (N 5 1121)
had a history of any thrombosis and 13% did not have a history of
thrombosis (N 5 174). The majority of patients with previous
thrombosis had a history of VTE (738 of 1121; 66%). These
patients were included in our analysis as main study population.
JAK2V617F was the most common reported mutation in patients in
whom MPN mutational status was assessed (Table 2).
Various antithrombotic treatment strategies were evaluated. In total,
623 patients received antiplatelet therapy, in most cases low-dose
aspirin (80 mg). VKA was the most common oral anticoagulant
treatment (467 patients), whereas more recent studies included 77
patients treated with DOACs.28-30,32,33 Few studies specified the
indication of antithrombotic treatment. A change of treatment
during study follow-up was common, but reasons for changing or
a rationale behind a different type of antithrombotic therapy were
frequently not reported. Treatment with cytoreductive agents was
common but rarely given without concomitant antithrombotic
therapy; 69% vs 8%, respectively.
Study quality
We addressed study quality using the ROBINS-I tool. Full details of
the risk of bias assessment for each study can be found in the
supplemental Data. Two studies had serious risk of bias, and the
remaining 9 studies were judged to have moderate risk of bias,
leading to an overall rating of moderate risk of bias. The main
sources of bias were confounding and the selection of patients.
Deviations from the intended interventions with patients crossing
over to another treatment differed largely per study and was in
almost half of the studies not assessable.
Outcomes
Recurrent thrombotic events. Our main study population
consisted of the patients with a history of VTE in the included
studies (N 5 738). Overall, 22.6% of evaluated patients had
a recurrent thrombotic event during follow-up, either arterial or
venous thrombosis (293 of 1295 patients; 10 studies).24-33 The
observed recurrence risk was highest in patients with single
antithrombotic treatment modalities or patients receiving neither
antithrombotic treatment nor cytoreduction. The overall evidence
was rated as very uncertain for all interventions because of the
observational nature of the data, high risk of bias in the included
studies, inconsistency in the results and imprecision in the
estimates.
Six studies (555 patients) described patient cohorts in whom all
patients had a VTE at study baseline; 254 patients with splanchnic
vein thrombosis, 298 with deep vein thrombosis and/or pulmonary
embolism, 2 with cerebral venous sinus thrombosis, and 1 with
superficial thrombophlebitis.27-29,31-33 Results of an exploratory
comparative analysis of studies in which all patients had either
splanchnic vein thrombosis or deep vein thrombosis/pulmonary
embolism as baseline event can be found in supplemental
Table 1.27-29,31
Few studies specified whether recurrent thrombotic events con-
cerned recurrent arterial or venous thrombosis. In patients with
established recurrent VTE, the risk of recurrence ranged from
0.0% to 33.3% (median, 13.0%) and was highest when only
anticoagulant treatment was given in 21 of 72 patients (29.2%) on
VKA only and in 3 of 14 patients (21.4%) on DOAC only.
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Antiplatelet therapy with or without cytoreduction
Five studies reported recurrent arterial or venous thrombotic events
in 118 patients on antiplatelet therapy only and found a risk of
recurrence of 30.5% (95% CI, 22.4-39.6).24,29,31,32 Seven studies
reported recurrence in 452 patients on antiplatelet plus cytor-
eductive therapy, with recurrent events in 18.6% of patients (95%
CI, 15.1-22.5).24-29,31 Of 120 recurrent thrombotic events, nearly all
(118 of 120) were arterial. Recurrent VTE occurred in only 1 patient
on single antiplatelet therapy and 1 patient on antiplatelet therapy
and cytoreduction.
Oral anticoagulation with or without cytoreduction
In 6 studies reporting on 120 patients treated with oral anti-
coagulation only (either VKA or DOAC), 42 had a recurrent arterial
or venous thrombotic event (35.0%; 95% CI, 26.5-44.2).26,28-32
When oral anticoagulation was combined with cytoreductive
treatment, a pooled analysis of 8 studies involving 376 patients
showed a recurrence risk of 16.0% (95% CI, 12.4%-20.1%),
associated with an RR of 0.42 (95% CI, 0.19-0.19; I2 5 62.7%)
compared with patients on oral anticoagulation without concomi-
tant cytoreduction.26-33A sensitivity analysis per type of antico-
agulation showed that the risk of recurrence was high for both VKA
only and DOAC only treated patients: 39 of 106 (36.8%) and 3 of
14 (21.4%). This risk was significantly lower for both VKA and
DOAC when they were combined with cytoreduction (17.6% and
7.9%, respectively; Table 3).
The majority of the recurrent events were VTE (61 of 102
thrombotic events); 24 of 42 thrombotic events in patients on oral
anticoagulation only, either VKA or DOAC, whereas this was 37 of
60 recurrent events when oral anticoagulation was combined with
cytoreduction. Recurrent VTE was diagnosed in 2 of 63 (3.2%;
95% CI, 0.4-11.0) patients treated with DOAC plus cytoreduction
and in 35 of 268 (13.1%; 95% CI 9.3-17.7) patients on VKA plus
cytoreduction.
Two large cohort studies (387 patients overall) reported incidence
rates of recurrent arterial or venous thrombosis on and off VKA
therapy. In 181 patients with MPN with splanchnic vein thrombosis
the incidence rate of recurrent thrombosis on VKA therapy was 3.9
per 100-patient years compared with 7.2 per 100-patient years off
VKA therapy.28 A cohort of 206 patients with MPN with deep vein
thrombosis and/or pulmonary embolism reported an incidence rate
of recurrent thrombosis of 4.7 per 100-patient years on VKA
therapy, as it was 8.9 per 100-patient years off VKA therapy.29
Antiplatelet therapy plus oral anticoagulation with or
without cytoreduction
Five studies reported on 53 patients receiving the combination of
antiplatelet therapy and oral anticoagulation, with or without
cytoreduction.26-29,31 In 9 of 37 (24.3%; 95% CI, 11.8-41.2)
patients receiving antiplatelet therapy plus oral anticoagulation and
cytoreduction, a recurrent arterial or venous thrombotic even was
diagnosed, similar to 4 of 16 patients without additional cytor-
eduction (25.0%; 95%CI, 7.3-52.4). Approximately half (6 of 13) of
these recurrent events were of venous origin.
Cytoreduction only or no antithrombotic/
cytoreductive treatment
Six studies included 134 patients treated with cytoreduction only or
patients with neither antithrombotic treatment nor cytoreductive
treatment. No difference in recurrence risk was observed in patients
receiving cytoreduction only or no treatment at all and the risk was
5787 studies identified by
systematic search in MEDLINE,










2 data from authors
10 studies included in synthesis:
• 1 prospective cohort study
• 8 retrospective cohort studies
• 1 case series
5430 excluded after title
and abstract evaluation
284 studies excluded after full-text evaluation:
• 77 inclusion criteria not met
• 30 duplicate data
• 40 abstract only, insufficient data
• 110 different outcome or no differentiation
   in prior thromboembolic events
• 7 review, survey, meta-analyses
• 20 missing or unclear data
Figure 1. Flowchart of study selection.
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high in both groups: 30.7% and 36.4%, respectively (RR, 0.50;
95% CI, 0.37-0.67; I2 5 0%). Of 43 recurrent thrombotic events
overall, only 9 were venous events.24,26-29,32
Bleeding events
In total, 94 bleeding events were reported in the 10 included
studies.24-33 Most included studies did not discern major, clinically
relevant nonmajor, or minor bleeding events or specification per
treatment strategy. The majority of bleeding events occurred on
antiplatelet therapy only or in combination with oral anticoagulation
(60%), primarily of gastrointestinal origin. In the 77 DOAC-treated
patients, 3 major bleeding episodes (all related to interventions), 3
clinically relevant nonmajor episodes, and 2 minor bleeding
episodes were observed.28-30,32,33
Overall survival
Mortality rates were reported in 8 of 10 studies (950 patients).24-31
The overall survival rate was high (93%). In 15 of 77 patients (19%),
Table 1. Characteristics of the 10 included studies
Study year Study characteristics Study population MPN Follow-up, y Antithrombotic treatment Reference
1991 Retrospective cohort N 5 103 ET Mean 4.8 Antiplatelet 6 cytoreduction (N 5 74) 24
Single center Age: 9-88 y Cytoreduction only (N 5 15)
Italy ♀/♂: 59/44 No treatment (N 5 14)
2002 Retrospective cohort N 5 118 ET Median 10 Antiplatelet 6 cytoreduction (N 5 118) 25
Single center Age: mean 62 y
Italy ♀/♂: 69/49
2008 Retrospective cohort N 5 494 ET, PV Median 5.3 Antiplatelet 6 cytoreduction (N 5 351) 26
Multicenter Age: median 62 y VKA 6 cytoreduction (N 5 79)
Italy ♀/♂: 255/239 VKA 1 antiplatelet 6 cytoreduction (N 5 11)
Cytoreduction only (N 5 40)
No treatment (N 5 13)
2011 Retrospective cohort N 5 44 ET, PV, MF, Unclassified Median 5.8 Antiplatelet only (N 5 6) 27
Single center Age: median 48 y VKA only (N 5 9)
Netherlands ♀/♂: 31/13 VKA 1 antiplatelet (N 5 6)
No treatment (N 5 23)
2016 Retrospective cohort N 5 181 ET, PV, PMF Median 3.2 Antiplatelet 1 cytoreduction (N 5 6) 28
Multicenter Age: median 48 y Anticoagulation 6 cytoreduction (N 5 156)
Multinational ♀/♂: 118/63 Anticoagulation 1 antiplatelet 6 cytoreduction (N 5 10)
Cytoreduction only (N 5 8)
No treatment (N 5 1)
2016 Retrospective cohort N 5 206 ET, PV, PMF Median 2.6 Antiplatelet 6 cytoreduction (N 5 11) 29
Multicenter Age: median 72 y Anticoagulation 6 cytoreduction (N 5 163)
Multinational ♀/♂: 114/92 Anticoagulation 1 antiplatelet 6 cytoreduction (N 5 19)
Cytoreduction only (N 5 9)
No treatment (N 5 5)
2017 Prospective cohort N 5 25 ET, PV Median 2.1 DOAC 6 cytoreduction (N 5 25) 30
Single center Age: median 75 y
France ♀/♂: 12/13
2018 Case-series N 5 14 ET, PV, Unclassified Median 7.4 VKA 6 cytoreduction (N 5 9) 31
Single center Age: mean 47 y Antiplatelet 6 cytoreduction (N 5 2)
Northern Ireland ♀/♂: 11/3 VKA 1 antiplatelet 6 cytoreduction (N 5 3)
No treatment (N 5 2)
2019 Retrospective cohort N 5 78 ET, PV, MF Median 5.4 Anticoagulation 6 cytoreduction (N 5 71) 32
Single center Age: median 53 y No anticoagulation (N 5 7)
Germany ♀/♂: 57 /25
2020 Retrospective cohort N 5 32 ET, PV, MF, Unclassified Median 2.1 33
Single center Age: median 50 y DOAC 1 cytoreduction (N 5 28)
United Kingdom ♀/♂: 18/14 DOAC 1 antiplatelet (N 5 4)
DVT, deep vein thrombosis; PV, polycythemia vera.




 http://ashpublications.org/bloodadvances/article-pdf/5/1/113/1796442/advancesadv2020003628.pdf by guest on 04 M
ay 2021
cause of death was directly related to the thrombotic event. Leukemic
transformation was reported in 31 patients (3%) and was considered
the cause of death in 8 patients (10%).
Discussion
Based on data from 10 observational studies, our systematic review
shows a high risk of recurrent thrombotic events in patients with
MPN with a history of VTE, even with long-term oral anticoagulant
treatment. Treatment regimens involving the combination of oral
anticoagulation and cytoreduction report the lowest risk of
recurrent VTE, with low risks of recurrent VTE in limited numbers
of patients in studies with DOACs. As direct comparisons of
different treatment strategies are lacking because of the absence of
randomized controlled trials, it is not possible to make suggestions
on an optimal antithrombotic regimen.
This systematic review summarizes the currently available evidence
on antithrombotic treatment in patients with an MPN and a history of
VTE. The available evidence, albeit with very low certainty and
moderate risk of bias, suggests that the combination of oral
anticoagulation and cytoreduction is associated with the lowest risk
of recurrent thrombosis in patients with MPN with a prior VTE, in line
with current clinical practice. Although the use of VKA is most
common in this population, DOACs may be a reasonable alterna-
tive. The limited number of studies on DOAC-treated patients
identified in our review showed relatively low risks of recurrent
thrombotic and bleeding events, but more data are definitely
needed. In addition, prospective studies evaluating DOACs for
treatment of unusual site VTE are anticipated and will be important
for patients with MPN, as these diseases are a known major risk
factor for splanchnic vein thrombosis, whereas DOAC prescription
is still off-label in these patients.34-36 Recent guidance from the
ISTH Scientific and Standardization Committee already suggests
using DOACs for treatment of splanchnic vein thrombosis in
noncirrhotic patients, including patients with underlying MPN, if not
contraindicated by severe liver dysfunction.37 A combination of oral
anticoagulation and antiplatelet therapy has been suggested as an
effective long-term treatment option in patients with MPN and
splanchnic vein thrombosis,26,27 but based on the available data of
this review, there seems insufficient evidence to support this
combination as first-line treatment.
The majority of our study population received cytoreductive therapy
combined with antithrombotic therapy. Details of cytoreductive
treatment, such as the type and indication for cytoreduction were
frequently not specified, whereas concomitant phlebotomies were
only reported in 3 of 10 studies and not in relation to study
outcomes. Hence, the net clinical benefit of cytoreductive therapy
remains uncertain, as well as the optimal type of cytoreductive
treatment (eg, hydroxyurea, [peg]interferon, or ruxolitinib).
This review has clear limitations. Both the amount and the quality of
the available data form serious limitations in this review. Initially only
8 studies met our inclusion criteria. An additional 20 studies were
potentially eligible but did not specify thrombotic events during
follow-up or per treatment strategy. We requested additional data
from several research groups, which enabled us to include 2
additional studies and obtain more data. Several landmark
randomized trials on antithrombotic treatment in patients with
Table 2. Baseline characteristics of studied patient population
(n 5 1295)
Characteristic n (%)
Sex, n (%) ♀ 744 (57)
♂ 555 (43)
Age, y Range: 47-75
MPN, n (%)
Essential thrombocythemia 700 (54)
Polycythemia vera 473 (37)
Primary myelofibrosis 103 (8)
Unclassified 19 (1)






Prior thrombosis, n (%)
Arterial thrombosis 383 (30)
Venous thrombosis 738 (57)
DVT/PE 278 (38)
Splanchnic vein thrombosis 286 (39)
Cerebral (sino)venous thrombosis 8 (1)
Not specified 162 (22)
Both arterial and venous thrombosis 8 (0.6)
*Proportion of patients in whom MPN mutational status was assessed.
CALR, calreticulin gene mutation; DVT, deep vein thrombosis; JAK2, janus kinase 2
(V617F) mutation; JAKex12, janus kinase 2 exon 12 mutation; MPL, myeloproliferative
leukemia virus oncogene mutation.





Relative risk (95% CI);
I2n/N %
Antiplatelet therapy only 36/118 30.5
Antiplatelet 1 cytoreduction 84/452 18.6 0.27 (0.07-1.04); 80.9%
Oral anticoagulation (any) 42/120 35.0
Oral anticoagulation (any) 1 cytoreduction 60/376 16.0 0.42 (0.19-0.92); 62.7%
Oral anticoagulation 1 antiplatelet therapy 4/16 25.0
Oral anticoagulation 1 antiplatelet 1
cytoreduction
9/37 24.3 0.60 (0.18-2.01); 36.3%
No antithrombotic treatment or cytoreduction 12/33 36.4
Cytoreduction only 31/101 30.7 0.50 (0.37-0.67); 0.0%
Recurrent thrombosis per type of oral anticoagulant
VKA only 39/106 36.8
VKA 1 cytoreduction 55/313 17.6 0.51 (0.23-1.14); 62.2%
DOAC only 3/14 21.4
DOAC 1 cytoreduction 5/63 7.9 0.21 (0.08-0.60); 16.9%
VKA 1 antiplatelet therapy 4/11 36.4
VKA 1 antiplatelet 1 cytoreduction 9/37 24.3 0.43 (0.16-1.15); 0%
DOAC 1 antiplatelet therapy 0/5 0% —
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MPN have been performed and were identified by our search but
were judged to be ineligible for inclusion in this review based on our
criteria because of missing data on either recurrent thrombosis or
treatment strategy. Almost all studies included in this review were
highly affected by confounding by indication and selection bias
because of their retrospective design, which is also reflected in the
overall moderate to severe risk of bias of the studies. Although the
use of risk of bias tools is disputed in observational studies, we
chose to address the study quality using the ROBINS-I tool.
Study outcomes were not consistently reported per treatment and
whether with or without cytoreductive therapy, and individual patient
data were hardly available. Moreover, we did not intend to perform
an individual patient data meta-analysis but on an analysis on study
level. This hampered any possibilities of performing a multivariable
analysis to adjust for confounding factors in our primary outcome
analysis. Planned subgroup analyses based on mutation status or
site of VTE were also not possible as sufficient data for meaningful
analyses could not be retrieved from the original studies. Therefore,
we cannot make any conclusive statements regarding differences in
outcomes or strategies for patients with a history of splanchnic vein
thrombosis or other types of VTE. We report the proportion of
patients with a recurrent thrombotic event, specifically recurrent
VTE, but the collected data does not allow exploring the association
between recurrence and disease duration, timing of recurrent event,
or its relation to treatment duration. Predefined subgroup analyses
evaluating outcomes in patients with VTE diagnosed before MPN
diagnosis or at or after MPN diagnosis were not possible because
of lack of individual patient data. Ideally, for comparative purposes,
we would have presented incidence rates per antithrombotic
treatment strategy. However, we were unable to do so given the
available data. Additionally, with the exception of 1 included case
series,31 we were unable to evaluate changes in antithrombotic
treatment during study follow-up. This is of importance, as not only
the risk of recurrent thrombosis but also bleeding complications
may require a change in antithrombotic therapy. Certainty of
evidence was further affected by imprecision, inconsistency in
results and significant heterogeneity. The comprehensive search
strategy, with well-defined inclusion and exclusion criteria and
accurate methods, however, are the strengths of this study.
The fact that we only identified 10 studies matching our inclusion
criteria implicates a lack of evidence and high-quality studies
investigating this important clinical issue. The great variety of
treatment strategies and heterogeneity in the studied patients also
reflect the clinical variety of patients with MPN and exhibit possible
difficulties that can be encountered when conducting research in
this population. Prospective studies evaluating antithrombotic
treatment of secondary prevention of MPN-related VTE are much
needed. A direct comparison between different antithrombotic
strategies in this population is lacking and ideally should be
evaluated in an adequately powered randomized clinical trial in
a clearly defined study population. Such a trial could provide
urgently needed data on the safety and efficacy of the different
anticoagulants, for instance VKA vs DOAC, in MPN patients.
Additionally, it could contribute to clinical decision making regarding
the net clinical benefit of adding antiplatelet or cytoreductive
therapy to anticoagulation for prevention of recurrent thrombosis.
In summary, evidence on the optimal long-term antithrombotic
treatment of VTE in patients with MPN is based on observational
studies only, at high risk of bias and with imprecise findings. This
systematic review reports a high risk of recurrent thrombosis in
patients with MPN with a history of VTE despite anticoagulant
treatment. Our data suggest that antithrombotic treatment using
a combination of oral anticoagulation and cytoreduction may provide
the lowest risk of recurrent thrombosis albeit with very little precision
because of limited data and an analysis on study level only. The role of
cytoreduction in the different subtypes of patients with VTE in MPN
remains to be determined. Adequately powered randomized clinical
trials are needed for proper assessment of the optimal antithrombotic
treatment strategy in patients with an MPN and a history of VTE.
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